Loading…
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.7B | $888M | $683M | $411M | -332.5% | 114.5% | -287.9% |
| 2024 | $807M | $-120M | $-363M | $-182M | 33.1% | -14.0% | -42.0% |
| 2023 | $938M | $-330M | $-627M | $-279M | 76.6% | 34.2% | 12.1% |
| 2022 | $699M | $-368M | $-559M | $-509M | 161.1% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 698.80 | 937.82 | 806.78 | 1,730.66 |
| Operating Revenue | - | 698.80 | 937.82 | 806.78 | 1,730.66 |
| Cost Of Revenue | - | 44.68 | 65.49 | 57.40 | 47.01 |
| Gross Profit | - | 654.12 | 872.34 | 749.38 | 1,683.64 |
| Operating Expense | - | 1,094.05 | 1,221.74 | 896.13 | 827.13 |
| Research And Development | - | 651.50 | 666.56 | 534.48 | 455.25 |
| Selling General And Administration | - | 326 | 332.54 | 300.91 | 347.14 |
| Total Expenses | - | 1,138.73 | 1,287.22 | 953.53 | 874.15 |
| Operating Income | - | -439.92 | -349.40 | -146.75 | 856.51 |
| Total Operating Income As Reported | - | -447.41 | -439.50 | -302.57 | 866.94 |
| EBITDA | - | -367.78 | -330.34 | -120.46 | 887.66 |
| Normalized EBITDA | - | -360.30 | -102.68 | 35.36 | 877.24 |
| EBIT | - | -496.62 | -566.93 | -196.13 | 848.85 |
| Interest Expense | - | 90.87 | 129.18 | 166.99 | 152.23 |
| Net Interest Income | - | -90.87 | -129.18 | -166.99 | -152.23 |
| Other Non Operating Income Expenses | - | -49.21 | 10.13 | 106.44 | -18.09 |
| Other Income Expense | - | -56.69 | -217.53 | -49.38 | -7.66 |
| Interest Expense Non Operating | - | 90.87 | 129.18 | 166.99 | 152.23 |
| Net Non Operating Interest Income Expense | - | -90.87 | -129.18 | -166.99 | -152.23 |
| Pretax Income | - | -587.49 | -696.11 | -363.12 | 696.62 |
| Tax Provision | - | -28.47 | -69.51 | 0.18 | 13.98 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -0.36 | -22.77 | -32.72 | 0.21 |
| Net Income Continuous Operations | - | -559.02 | -626.60 | -363.30 | 682.64 |
| Net Income From Continuing And Discontinued Operation | - | -559.02 | -626.60 | -363.30 | 682.64 |
| Net Income From Continuing Operation Net Minority Interest | - | -559.02 | -626.60 | -363.30 | 682.64 |
| Net Income | - | -559.02 | -626.60 | -363.30 | 682.64 |
| Net Income Common Stockholders | - | -559.02 | -626.60 | -363.30 | 682.64 |
| Net Income Including Noncontrolling Interests | - | -559.02 | -626.60 | -363.30 | 682.64 |
| Normalized Income | - | -551.90 | -421.71 | -240.19 | 672.43 |
| Diluted NI Availto Com Stockholders | - | -559.02 | -626.60 | -363.30 | 682.64 |
| Basic Average Shares | - | 71.73 | 74.84 | 76.85 | 79.53 |
| Diluted Average Shares | - | 71.73 | 74.84 | 76.85 | 88.31 |
| Reconciled Depreciation | - | 128.84 | 236.59 | 75.66 | 38.82 |
| Reconciled Cost Of Revenue | - | 32.40 | 51.53 | 42.47 | 32.94 |
| Total Unusual Items | - | -7.48 | -227.66 | -155.82 | 10.43 |
| Total Unusual Items Excluding Goodwill | - | -7.48 | -227.66 | -155.82 | 10.43 |
| Special Income Charges | - | -7.48 | -227.66 | -155.82 | 10.43 |
| Other Special Charges | - | - | 137.56 | - | - |
| Impairment Of Capital Assets | - | 33.38 | 217.80 | 160.30 | -9.63 |
| Restructuring And Mergern Acquisition | - | -25.90 | -127.70 | -4.47 | -0.80 |
| Depreciation Amortization Depletion Income Statement | - | 116.55 | 222.64 | 60.74 | 24.74 |
| Depreciation And Amortization In Income Statement | - | 116.55 | 222.64 | 60.74 | 24.74 |
| Amortization | - | 116.55 | 222.64 | 60.74 | 24.74 |
| Amortization Of Intangibles Income Statement | - | 116.55 | 222.64 | 60.74 | 24.74 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| PTC Therapeutics, Inc.this co. | PTCT | $5.9B | 8.58↓ discount | - | -332.5% | 7.46 |
| Alkermes plc | ALKS | $7.2B | 29.92 | 3.97 | 13.3% | 20.89 |
| Glaukos Corporation | GKOS | $7.1B | -38.08 | 10.89 | -28.6% | -49.02 |
| Protagonist Therapeutics, Inc. | PTGX | $6.6B | -50.79 | 10.75 | -21.2% | -41.39 |
| TG Therapeutics, Inc. | TGTX | $6.2B |
| - |
| - |
| - |
| - |
| - |
| - |
| 13.88 |
| 9.58 |
| 69.0% |
| 47.51 |
| Teleflex Incorporated | TFX | $5.8B | -6.46 | 1.87 | -29.0% | 27.09 |
| Apellis Pharmaceuticals, Inc. | APLS | $5.3B | 234.62 | 14.19 | 6.0% | 75.16 |
| Ligand Pharmaceuticals Incorporated | LGND | $4.7B | 37.99 | 4.65 | 12.2% | 25.35 |
| Indivior Pharmaceuticals, Inc. | INDV | $4.4B | 21.08 | -44.71 | -212.1% | 15.07 |
| Peer Median | - | 17.48 | 7.11 | -7.6% | 23.12 | |